Evaluating Tumor-Directed PET Imaging of mCRPC Bone Metastases Using Zr-89-J591

February 7, 2014
Scott T. Tagawa, MD

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

Clinical Pearls:

  • Following standard CT/MRI, bone scintigraphy, and FDG PET imaging, 5 mCi of Zr-89-J591 was administered intravenously and Zr-89-J591 was imaged 6-8 days after injection
  • The study showed that using J591 PET/CT detects bone disease at greater rates than any other imaging modality tested
  • A number of sites that were negative on CT, bone scan, and standard FDG PET imaging were positive by J591. A biopsy confirmed that they were positive